Breast cancer (BRCA) is one of the most frequent malignant tumors with the highest incidence of cancer and the second most common oncologic cause of death in women. BRCA can be classified into different molecular subtypes, such as basal‐like, represented by triple‐negative BRCA (estrogen receptor [ER] negative, progesterone receptor [PR] negative, and human epidermal growth factor receptor 2 [HER‐2] negative). This study aims to determine whether radiomics features extracted from magnetic resonance imaging (MRI) could be used to distinguish various BRCA molecular subtypes. This study retrospectively collected a dataset of 922 BRCA patients with MRIs and experimental genomic profiles. A genetic algorithm is then employed to select the optimal MRI features for each subproblem. Subsequently, stacking ensemble learning is implemented to learn these features and generate the prediction outcomes. Our model showed a significant performance of 0.700, 0.732, and 0.642 (area under the curve; AUC) in predicting ER, PR, and HER‐2 statuses. For multiclassification of Luminal A, Luminal B, HER2, and TNBC, the AUCs reached 0.672, 0.624, 0.639, and 0.669, respectively. Our model is superior in most subtypes compared to the state‐of‐the‐art predictors on the same dataset. In conclusion, genetic algorithm and ensemble learning can be suitable for BRCA subtype classification with high performance.
{"title":"Using ensemble learning and genetic algorithm on magnetic resonance imaging radiomics to classify molecular subtypes of breast cancer","authors":"N. Le, D. Ho, Hoang Dang Khoa Ta, H. Nguyen","doi":"10.1002/prm2.12089","DOIUrl":"https://doi.org/10.1002/prm2.12089","url":null,"abstract":"Breast cancer (BRCA) is one of the most frequent malignant tumors with the highest incidence of cancer and the second most common oncologic cause of death in women. BRCA can be classified into different molecular subtypes, such as basal‐like, represented by triple‐negative BRCA (estrogen receptor [ER] negative, progesterone receptor [PR] negative, and human epidermal growth factor receptor 2 [HER‐2] negative). This study aims to determine whether radiomics features extracted from magnetic resonance imaging (MRI) could be used to distinguish various BRCA molecular subtypes. This study retrospectively collected a dataset of 922 BRCA patients with MRIs and experimental genomic profiles. A genetic algorithm is then employed to select the optimal MRI features for each subproblem. Subsequently, stacking ensemble learning is implemented to learn these features and generate the prediction outcomes. Our model showed a significant performance of 0.700, 0.732, and 0.642 (area under the curve; AUC) in predicting ER, PR, and HER‐2 statuses. For multiclassification of Luminal A, Luminal B, HER2, and TNBC, the AUCs reached 0.672, 0.624, 0.639, and 0.669, respectively. Our model is superior in most subtypes compared to the state‐of‐the‐art predictors on the same dataset. In conclusion, genetic algorithm and ensemble learning can be suitable for BRCA subtype classification with high performance.","PeriodicalId":40071,"journal":{"name":"Precision Medical Sciences","volume":"12 1","pages":"104 - 112"},"PeriodicalIF":0.5,"publicationDate":"2022-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46595855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Endoscopic retrograde cholangiopancreatography (ERCP), is an invasive procedure with a high complication rate used in the diagnosis and treatment of pancreaticobiliary system diseases. A system that grading the difficulty and complexity of the ERCP procedure has been developed by the American Society of Gastrointestinal Endoscopy (ASGE). The aim of the study is to evaluate the degree of difficulty of ERCP procedures according to the ASGE grading system and its effectiveness in predicting the success and complications of the procedure. A total of 600 patients who underwent ERCP were evaluated retrospectively. Of all ERCP procedures, 5.5% were classified as ASGE 1, 46.8% as ASGE 2, 39% as ASGE 3, and 8.6% as ASGE 4. In all procedures, the successful cannulation rate was 96.3%, the technical success rate was 96%, and the clinical success rate was 94.8%. The procedure's success decreased linearly and the need for repetition increased linearly as the ASGE grade increased (p > .05). In terms of complications, there was no statistical difference between ASGE 1–3 and 4. We believe that the ASGE grading system will be useful in clinical practice, particularly for less experienced endoscopists in ERCP procedures.
{"title":"Evaluation of the success and complication rates of endoscopic retrograde cholangiography according to the difficulty of the procedure","authors":"T. Demir, Muge Ustaoglu","doi":"10.1002/prm2.12088","DOIUrl":"https://doi.org/10.1002/prm2.12088","url":null,"abstract":"Endoscopic retrograde cholangiopancreatography (ERCP), is an invasive procedure with a high complication rate used in the diagnosis and treatment of pancreaticobiliary system diseases. A system that grading the difficulty and complexity of the ERCP procedure has been developed by the American Society of Gastrointestinal Endoscopy (ASGE). The aim of the study is to evaluate the degree of difficulty of ERCP procedures according to the ASGE grading system and its effectiveness in predicting the success and complications of the procedure. A total of 600 patients who underwent ERCP were evaluated retrospectively. Of all ERCP procedures, 5.5% were classified as ASGE 1, 46.8% as ASGE 2, 39% as ASGE 3, and 8.6% as ASGE 4. In all procedures, the successful cannulation rate was 96.3%, the technical success rate was 96%, and the clinical success rate was 94.8%. The procedure's success decreased linearly and the need for repetition increased linearly as the ASGE grade increased (p > .05). In terms of complications, there was no statistical difference between ASGE 1–3 and 4. We believe that the ASGE grading system will be useful in clinical practice, particularly for less experienced endoscopists in ERCP procedures.","PeriodicalId":40071,"journal":{"name":"Precision Medical Sciences","volume":"12 1","pages":"4 - 9"},"PeriodicalIF":0.5,"publicationDate":"2022-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46798751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Chunqi Huang, Yannan Wang, Yi Wu, Sisi Lin, Rui Hao, Jin Yu, Lu Fang, Jin-pu Zhu, Di Zhao, Shengjia Tong, Yongkai Si, Tiantian Ye, Zeyu Wu, Hui Huang, Zhuoyan Wang, Ying Wang
Voriconazole is a first‐line medicine for treating invasive fungal infections. We evaluated the pharmacokinetics (PK) and safety of single/multiple doses of voriconazole injection of Hailing Pharmaceutical Group (Test, T), an imitation of Vfend® (Reference, R). Healthy subjects (n = 36) randomly received a once‐daily dose of T or R 3 or 4 mg/kg on Day 1 (single dose), a once‐daily dose of T or R 6 mg/kg on Day 4, and then six consecutive days for twice‐daily doses of T or R 3 or 4 mg/kg (multiple doses). The plasma was collected up to 72 h at time points after dosing on Day 1/10. Samples were measured by the liquid chromatography tandem mass spectrometry method. PK parameters were confirmed according to a non‐compartmental model. The relationship between the PK profiles of T and R revealed the different behavior in 3‐ and 4‐mg/kg groups. After single/multiple doses in the 3‐mg/kg group, the mean value for the area under the plasma concentration–time curve (AUC0−t, AUC0−∞) of R is about twice T. However, there was a high degree of similarity in the 4‐mg/kg group. The maximum plasma concentration (Cmax) of T and R showed no noticeable difference in the two groups. The median Tmax of T and R were within 2.0–2.13 h in the 3‐mg/kg group and 2.0–2.17 h in the 4‐mg/kg group. Severe adverse events did not occur. No clinically significant differences were found in safety and tolerance between T and R. This clinical study indicated that voriconazole injection might provide a safer alternative medicine.
{"title":"Pharmacokinetics, safety of a single dose and multiple doses of voriconazole injection of two formulations, in Chinese healthy volunteers","authors":"Chunqi Huang, Yannan Wang, Yi Wu, Sisi Lin, Rui Hao, Jin Yu, Lu Fang, Jin-pu Zhu, Di Zhao, Shengjia Tong, Yongkai Si, Tiantian Ye, Zeyu Wu, Hui Huang, Zhuoyan Wang, Ying Wang","doi":"10.1002/prm2.12086","DOIUrl":"https://doi.org/10.1002/prm2.12086","url":null,"abstract":"Voriconazole is a first‐line medicine for treating invasive fungal infections. We evaluated the pharmacokinetics (PK) and safety of single/multiple doses of voriconazole injection of Hailing Pharmaceutical Group (Test, T), an imitation of Vfend® (Reference, R). Healthy subjects (n = 36) randomly received a once‐daily dose of T or R 3 or 4 mg/kg on Day 1 (single dose), a once‐daily dose of T or R 6 mg/kg on Day 4, and then six consecutive days for twice‐daily doses of T or R 3 or 4 mg/kg (multiple doses). The plasma was collected up to 72 h at time points after dosing on Day 1/10. Samples were measured by the liquid chromatography tandem mass spectrometry method. PK parameters were confirmed according to a non‐compartmental model. The relationship between the PK profiles of T and R revealed the different behavior in 3‐ and 4‐mg/kg groups. After single/multiple doses in the 3‐mg/kg group, the mean value for the area under the plasma concentration–time curve (AUC0−t, AUC0−∞) of R is about twice T. However, there was a high degree of similarity in the 4‐mg/kg group. The maximum plasma concentration (Cmax) of T and R showed no noticeable difference in the two groups. The median Tmax of T and R were within 2.0–2.13 h in the 3‐mg/kg group and 2.0–2.17 h in the 4‐mg/kg group. Severe adverse events did not occur. No clinically significant differences were found in safety and tolerance between T and R. This clinical study indicated that voriconazole injection might provide a safer alternative medicine.","PeriodicalId":40071,"journal":{"name":"Precision Medical Sciences","volume":" 2","pages":"186 - 194"},"PeriodicalIF":0.5,"publicationDate":"2022-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41253687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Abnormal SORT1 expression has been reported in various cancers. However, the expression and function of SORT1 in hepatocellular carcinoma (HCC) remain to be explored. This study aims to explore the expression and function of SORT1 and to identify its co‐expressed genes in HCC. Various gene expression databases were applied in our analysis. We found SORT1 was up‐regulated in HCC tumor tissues and high SORT1 expression level was associated with worse overall survival (OS). Co‐expressed genes with SORT1 and its potential regulators were explored using LinkedOmics. Functional network analysis of co‐expressed genes by Metascape revealed that they participated in aberrant lipid metabolism, AMPK signaling pathway, and PPAR signaling pathway which were all strongly linked to the pathogenesis of HCC. In addition, co‐expression genes were analyzed by Cytoscape to identify their hub genes, which included CYB5A, CYP2C9, CYP3A5, CYP4A11, and POR. The mRNA expression level of CYP2C9, CYP3A5, and CYP4A11 were down‐regulated in HCC tumor tissues via GEPIA. High hub genes expression level was associated with better OS and progression free survival (PFS) in HCC. The correlations between SORT1 and hub genes with cancer immune infiltrates were investigated by TIMER. Notably, SORT1 and hub genes expression was positively correlated with infiltrating levels of different immune cells. Our findings suggested that high SORT1 expression level predicted dismal prognosis in HCC and its possible mechanism was immune‐related.
{"title":"Prognostic potential and mechanism of SORT1 and its co‐expressed genes in hepatocellular carcinoma based on integrative analysis of multiple database","authors":"Minjie Lin, Mengying Zhu, Tingqiu Ge, Naiying Lu, Xiling Fu, Jia‐song Chang","doi":"10.1002/prm2.12084","DOIUrl":"https://doi.org/10.1002/prm2.12084","url":null,"abstract":"Abnormal SORT1 expression has been reported in various cancers. However, the expression and function of SORT1 in hepatocellular carcinoma (HCC) remain to be explored. This study aims to explore the expression and function of SORT1 and to identify its co‐expressed genes in HCC. Various gene expression databases were applied in our analysis. We found SORT1 was up‐regulated in HCC tumor tissues and high SORT1 expression level was associated with worse overall survival (OS). Co‐expressed genes with SORT1 and its potential regulators were explored using LinkedOmics. Functional network analysis of co‐expressed genes by Metascape revealed that they participated in aberrant lipid metabolism, AMPK signaling pathway, and PPAR signaling pathway which were all strongly linked to the pathogenesis of HCC. In addition, co‐expression genes were analyzed by Cytoscape to identify their hub genes, which included CYB5A, CYP2C9, CYP3A5, CYP4A11, and POR. The mRNA expression level of CYP2C9, CYP3A5, and CYP4A11 were down‐regulated in HCC tumor tissues via GEPIA. High hub genes expression level was associated with better OS and progression free survival (PFS) in HCC. The correlations between SORT1 and hub genes with cancer immune infiltrates were investigated by TIMER. Notably, SORT1 and hub genes expression was positively correlated with infiltrating levels of different immune cells. Our findings suggested that high SORT1 expression level predicted dismal prognosis in HCC and its possible mechanism was immune‐related.","PeriodicalId":40071,"journal":{"name":"Precision Medical Sciences","volume":"11 1","pages":"161 - 173"},"PeriodicalIF":0.5,"publicationDate":"2022-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47264325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
It aims to examine the correlation between the expression of YTHDF1 and YTHDF2 and the clinical, pathological, and prognostic factors in HCC. The study was done using statistics from TCGA to establish the noted relationship. The degree of YTHDF1 and YTHDF2 protein expression in 88 HCC as well as the adjacent tissues was then determined through IHC examination, and we examined how that expression linked with other clinicopathological traits and clinical outcomes. Bioinformatics examination revealed that YTHDF1 and YTHDF2 expression was increased in HCC tissues, and poor pathology grade and prognosis were linked to high expression. YTHDF1 protein expression in IHC was notably higher in HCC tissue (p = .023). It was associated with age (p = .002) but not with other clinicopathological characteristics or prognoses. When compared to paraneoplastic tissues, the expression of the protein YTHDF2 was considerably higher in HCC tissues (p < .0001); and its high expression due to worse pathological grading (p = .035), higher alpha fetoprotein expression (p = .04), higher tumor recurrence (p = .023), lower overall survival rate (p = .011), and lower recurrence free survival rate (p = .005). A separate predictive factor for determining recurrence‐free survival in HCC was YTHDF2. A novel molecular marker called YTHDF2 may be used to assess HCC patients' prognoses.
{"title":"Clinical implications of m6A‐related regulators YTHDF1 and YTHDF2 in hepatocellular carcinoma","authors":"Nanfang Qu, Xuemei Zhang, Xianbin Wu, Xia Zhou, Zhejun Deng, L. Ma, Yanhua Liu, Wenhong Ge, Huanghuang Jiang, Long-Yao Xu, Haixing Jiang","doi":"10.1002/prm2.12085","DOIUrl":"https://doi.org/10.1002/prm2.12085","url":null,"abstract":"It aims to examine the correlation between the expression of YTHDF1 and YTHDF2 and the clinical, pathological, and prognostic factors in HCC. The study was done using statistics from TCGA to establish the noted relationship. The degree of YTHDF1 and YTHDF2 protein expression in 88 HCC as well as the adjacent tissues was then determined through IHC examination, and we examined how that expression linked with other clinicopathological traits and clinical outcomes. Bioinformatics examination revealed that YTHDF1 and YTHDF2 expression was increased in HCC tissues, and poor pathology grade and prognosis were linked to high expression. YTHDF1 protein expression in IHC was notably higher in HCC tissue (p = .023). It was associated with age (p = .002) but not with other clinicopathological characteristics or prognoses. When compared to paraneoplastic tissues, the expression of the protein YTHDF2 was considerably higher in HCC tissues (p < .0001); and its high expression due to worse pathological grading (p = .035), higher alpha fetoprotein expression (p = .04), higher tumor recurrence (p = .023), lower overall survival rate (p = .011), and lower recurrence free survival rate (p = .005). A separate predictive factor for determining recurrence‐free survival in HCC was YTHDF2. A novel molecular marker called YTHDF2 may be used to assess HCC patients' prognoses.","PeriodicalId":40071,"journal":{"name":"Precision Medical Sciences","volume":"11 1","pages":"174 - 185"},"PeriodicalIF":0.5,"publicationDate":"2022-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41528209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Linezolid‐induced black hairy tongue (BHT) is an uncommon side effect. We present a case of linezolid induced BHT and evaluate relevant literature from the home and worldwide. Its goal is to offer a secure and appropriate foundation for clinical drug usage. A 23‐year‐old male with recurrent boil infection erroneously reported by gram‐positive methicillin‐resistant Staphylococcus aureus (MRSA) by pus culture, which was misdiagnosed by a small clinic (diagnostic center) in a rural region of Bangladesh where he had previously been treated for that reoccurring boil infection. The patient was actually suffering from a different pus‐forming bacteria (Klebsiella), a gram‐negative bacterium that was just found after careful C/S report. Linezolid was administered to the patient 600 mg q12h orally in tablet after discharge from that rural clinic. On the 14th day following oral treatment, the patient presented to the hospital with BHT but no other atypical taste complaints. However, all symptoms were tolerable, and he finished the linezolid treatment period. After withdrawing from the medicine, all tongue symptoms vanished. Following a thorough study, it was determined that this patient had BHT brought on by drug linezolid. Long‐term linezolid usage is associated with neuropathies and bone marrow suppression. There is, however, little information about an uncommon adverse effect, black hairy tongue. We present here a case of linezolid induced BHT in a patient who was misdiagnosed. Also covered are the etiology, pathophysiology, diagnosis, and management of black hairy tongue.
{"title":"Black‐brown hairy tongue: An unusual adverse effect of linezolid","authors":"Ashrafur Rahaman Mahadi, M. I. Majumder","doi":"10.1002/prm2.12083","DOIUrl":"https://doi.org/10.1002/prm2.12083","url":null,"abstract":"Linezolid‐induced black hairy tongue (BHT) is an uncommon side effect. We present a case of linezolid induced BHT and evaluate relevant literature from the home and worldwide. Its goal is to offer a secure and appropriate foundation for clinical drug usage. A 23‐year‐old male with recurrent boil infection erroneously reported by gram‐positive methicillin‐resistant Staphylococcus aureus (MRSA) by pus culture, which was misdiagnosed by a small clinic (diagnostic center) in a rural region of Bangladesh where he had previously been treated for that reoccurring boil infection. The patient was actually suffering from a different pus‐forming bacteria (Klebsiella), a gram‐negative bacterium that was just found after careful C/S report. Linezolid was administered to the patient 600 mg q12h orally in tablet after discharge from that rural clinic. On the 14th day following oral treatment, the patient presented to the hospital with BHT but no other atypical taste complaints. However, all symptoms were tolerable, and he finished the linezolid treatment period. After withdrawing from the medicine, all tongue symptoms vanished. Following a thorough study, it was determined that this patient had BHT brought on by drug linezolid. Long‐term linezolid usage is associated with neuropathies and bone marrow suppression. There is, however, little information about an uncommon adverse effect, black hairy tongue. We present here a case of linezolid induced BHT in a patient who was misdiagnosed. Also covered are the etiology, pathophysiology, diagnosis, and management of black hairy tongue.","PeriodicalId":40071,"journal":{"name":"Precision Medical Sciences","volume":"11 1","pages":"209 - 212"},"PeriodicalIF":0.5,"publicationDate":"2022-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46017568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Marcelo Marcos Opolski, Vitor Teixeira Maito, Aedra Carla Bufalo Kawassaki, Janaína Carla da Silva, R. Kern, D. Rech, Stefania Tagliari de Oliveira, Pâmela Lonardoni Micheletti, C. Panis, S. Grassiolli
Herein, we evaluated the salivary and plasmatic levels of tumor necrosis factor‐alpha (TNF‐α) in women diagnosed with breast cancer (BC; n = 20) versus women with benign breast conditions (Control; n = 29) and correlated the TNF‐α findings with BC clinicopathological parameters. TNF‐α was higher in the saliva samples from both groups than in plasma levels. BC and Control patients presented similar plasmatic and salivary values of TNF‐α. The salivary and plasmatic values of TNF‐α did not correlate with tumor features (estrogen receptor; progestogen receptor; Ki67, and HER2), indicating that its salivary content does not correlate with the parameters of disease prognosis. Therefore, TNF‐α is not helpful as a salivary marker in breast cancer patients.
{"title":"Salivary and plasmatic levels of tumor necrosis factor‐alpha do not correlate with the clinicopathological profile in breast cancer patients","authors":"Marcelo Marcos Opolski, Vitor Teixeira Maito, Aedra Carla Bufalo Kawassaki, Janaína Carla da Silva, R. Kern, D. Rech, Stefania Tagliari de Oliveira, Pâmela Lonardoni Micheletti, C. Panis, S. Grassiolli","doi":"10.1002/prm2.12082","DOIUrl":"https://doi.org/10.1002/prm2.12082","url":null,"abstract":"Herein, we evaluated the salivary and plasmatic levels of tumor necrosis factor‐alpha (TNF‐α) in women diagnosed with breast cancer (BC; n = 20) versus women with benign breast conditions (Control; n = 29) and correlated the TNF‐α findings with BC clinicopathological parameters. TNF‐α was higher in the saliva samples from both groups than in plasma levels. BC and Control patients presented similar plasmatic and salivary values of TNF‐α. The salivary and plasmatic values of TNF‐α did not correlate with tumor features (estrogen receptor; progestogen receptor; Ki67, and HER2), indicating that its salivary content does not correlate with the parameters of disease prognosis. Therefore, TNF‐α is not helpful as a salivary marker in breast cancer patients.","PeriodicalId":40071,"journal":{"name":"Precision Medical Sciences","volume":"11 1","pages":"155 - 160"},"PeriodicalIF":0.5,"publicationDate":"2022-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42408210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nurul Ain Bt Khoruddin, W. Lim, L. Teh, Mohd Nur Fakhruzzaman Noorizhab, F. Z. Mohd Yusof, M. Z. Salleh
This cross‐sectional study aimed to profile 15 genetic markers associated with the risks of nutrient deficiencies and eating disinhibition behaviors that could lead to obesity among the Orang Asli (OA) and the Malays. The whole‐genome sequences of 98 OA and 96 Malay individuals were mined for these 15 genetic variants. The distributions of risk allele frequencies were then compared with other world populations to determine the impact of these genetic variations on the wellness of the two cohorts. The risk alleles include rs2025804 G, rs1800497 T, rs4680 G, rs602662 G, rs174547 C, and rs4654748 C, were commonly found among the OA and Malays and are likely to be pathogenic genetics variants for obesity. The risk allele frequencies differed significantly between the studied and the other five populations (p < .05). We believe that this is the first reported study on the genetic variants associated with nutrient deficiencies and eating disinhibition behaviors that are likely to increase risks of obesity among the OA and Malays.
{"title":"Toward precision nutrition: A cross‐sectional study on the genetic risks of nutrients deficiencies and eating behaviors among the Orang Asli and Malays","authors":"Nurul Ain Bt Khoruddin, W. Lim, L. Teh, Mohd Nur Fakhruzzaman Noorizhab, F. Z. Mohd Yusof, M. Z. Salleh","doi":"10.1002/prm2.12081","DOIUrl":"https://doi.org/10.1002/prm2.12081","url":null,"abstract":"This cross‐sectional study aimed to profile 15 genetic markers associated with the risks of nutrient deficiencies and eating disinhibition behaviors that could lead to obesity among the Orang Asli (OA) and the Malays. The whole‐genome sequences of 98 OA and 96 Malay individuals were mined for these 15 genetic variants. The distributions of risk allele frequencies were then compared with other world populations to determine the impact of these genetic variations on the wellness of the two cohorts. The risk alleles include rs2025804 G, rs1800497 T, rs4680 G, rs602662 G, rs174547 C, and rs4654748 C, were commonly found among the OA and Malays and are likely to be pathogenic genetics variants for obesity. The risk allele frequencies differed significantly between the studied and the other five populations (p < .05). We believe that this is the first reported study on the genetic variants associated with nutrient deficiencies and eating disinhibition behaviors that are likely to increase risks of obesity among the OA and Malays.","PeriodicalId":40071,"journal":{"name":"Precision Medical Sciences","volume":"11 1","pages":"146 - 154"},"PeriodicalIF":0.5,"publicationDate":"2022-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45890877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：